Co-Diagnostics Inc (CODX)

NASD · Healthcare · Medical Devices · USA

Co-Diagnostics Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

Co-Diagnostics develops and sells reagents for PCR diagnostic tests that detect nucleic acid molecules for infectious diseases. Using proprietary Co-Primers technology, the company has obtained regulatory approvals in multiple countries for tests detecting COVID-19, influenza, tuberculosis, hepatitis, and other pathogens for clinical laboratory use. The company is developing the Co-Dx PCR platform for point-of-care testing.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Co-Diagnostics Inc stock.

Our verdict on CODX

Undervalued: intrinsic value $0.93 per share, market price $0.20, margin of safety 78.5% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $0.93; the price of $0.20 is 78% below that value.

ETFs with the most weight in CODX

More on CODX

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Is CODX undervalued or overvalued?

CODX is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.93; the price of $0.20 is 78% below that value.

What is the intrinsic value of CODX?

$0.93 per share (as of the 2026-11-17 close), against a market price of $0.20. That is a margin of safety of 78.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.